Targeting tumor antigen Mesothelin by CAR-NK-92 cells as an effective therapy against ovarian cancer cells

Background Ovarian cancer is typically diagnosed at an advanced stage with peritoneal metastases and remains associated with high relapse rates and limited therapeutic options. While chimeric antigen receptor (CAR)-based immunotherapies have demonstrated remarkable success in hematologic malignancies, their implementation against solid tumors remains challenging due to tumor heterogeneity and an immunosuppressive microenvironment. Mesothelin, a cell-surface glycoprotein overexpressed in ovarian cancer and largely absent in healthy tissues, represents a promising therapeutic target. Material and methods Third-generation anti-Mesothelin CAR constructs containing CD28, 4-1BB, and CD3ζ signaling domains were introduced into NK-92 cells using self-inactivating (SIN) alpharetroviral or lentiviral vectors. CAR expression, vector copy numbers, and cytotoxic activity were evaluated in 2D and 3D co-culture models employing ovarian cancer cell lines (OVCAR3, A2780) and primary patient-derived tumor cells. Cytotoxicity was assessed through live-cell imaging and flow cytometry. Results Mesothelin was highly expressed in ovarian cancer cell lines and patient tumor samples, but minimally detected in healthy ovarian tissues. Alpharetroviral anti-Mesothelin CAR-NK-92 cells exhibited potent, antigen-dependent cytotoxicity against Mesothelin-high OVCAR3 and primary ovarian cancer cells in 2D models and pronounced tumor reduction in 3D spheroid assays. Additionally, alpharetroviral CAR-NK-92 cells demonstrated greater cytotoxic activity compared to lentiviral counterparts. Conclusion Our findings demonstrate significant antitumor activity of alpharetroviral anti-Mesothelin CAR-NK-92 cells in vitro, underscoring Mesothelin as a promising therapeutic target in ovarian cancer. The favorable safety profile and high performance of alpharetroviral vectors support their further development as a platform for next-generation CAR-NK cell therapies against solid malignancies.

Authors

Institutions

Publication Details

Journal
Journal of Ovarian Research
Published
2026-11-19
DOI
https://doi.org/10.1186/s13048-026-02349-7
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting tumor antigen Mesothelin by CAR-NK-92 cells as an effective therapy against ovarian cancer cells

Peter Hillemanns, Jan C. Kamp, Lavinia Neubert, Dirk Schaudien et al.
Journal of Ovarian Research
CAR-T cell therapy research
article

Targeting tumor antigen Mesothelin by CAR-NK-92 cells as an effective therapy against ovarian cancer cells

Peter Hillemanns, Jan C. Kamp, Lavinia Neubert, Dirk Schaudien, Thilo Dörk, Jens Hachenberg, Agnieszka Seyda, Malte Gronewold, Lisa‐Marie Speith, Rüdiger Klapdor, Robert Polten, Ivana Kutle, Jan Lennart Stalp, Michael Alexander Morgan, Axel Schambach, Anjali Shrivastava
article en

Abstract

Background Ovarian cancer is typically diagnosed at an advanced stage with peritoneal metastases and remains associated with high relapse rates and limited therapeutic options. While chimeric antigen receptor (CAR)-based immunotherapies have demonstrated remarkable success in hematologic malignancies, their implementation against solid tumors remains challenging due to tumor heterogeneity and an immunosuppressive microenvironment. Mesothelin, a cell-surface glycoprotein overexpressed in ovarian cancer and largely absent in healthy tissues, represents a promising therapeutic target. Material and methods Third-generation anti-Mesothelin CAR constructs containing CD28, 4-1BB, and CD3ζ signaling domains were introduced into NK-92 cells using self-inactivating (SIN) alpharetroviral or lentiviral vectors. CAR expression, vector copy numbers, and cytotoxic activity were evaluated in 2D and 3D co-culture models employing ovarian cancer cell lines (OVCAR3, A2780) and primary patient-derived tumor cells. Cytotoxicity was assessed through live-cell imaging and flow cytometry. Results Mesothelin was highly expressed in ovarian cancer cell lines and patient tumor samples, but minimally detected in healthy ovarian tissues. Alpharetroviral anti-Mesothelin CAR-NK-92 cells exhibited potent, antigen-dependent cytotoxicity against Mesothelin-high OVCAR3 and primary ovarian cancer cells in 2D models and pronounced tumor reduction in 3D spheroid assays. Additionally, alpharetroviral CAR-NK-92 cells demonstrated greater cytotoxic activity compared to lentiviral counterparts. Conclusion Our findings demonstrate significant antitumor activity of alpharetroviral anti-Mesothelin CAR-NK-92 cells in vitro, underscoring Mesothelin as a promising therapeutic target in ovarian cancer. The favorable safety profile and high performance of alpharetroviral vectors support their further development as a platform for next-generation CAR-NK cell therapies against solid malignancies.

Journal of Ovarian Research
Boston Children's Hospital (US), Harvard University (US), Medizinische Hochschule Hannover (DE), Fraunhofer Institute for Toxicology and Experimental Medicine (DE), Dana-Farber Cancer Institute (US), German Center for Lung Research (DE), Albertinen Diakoniewerk (DE)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon